New diabetes drug shows safety over one year in japanese patients
NCT ID NCT01301833
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the long-term safety of MP-513 (Teneligliptin) in 462 Japanese adults with type 2 diabetes. Participants took the drug alone or with other oral diabetes medicines for 52 weeks. The main goal was to track side effects, and researchers also measured blood sugar control. The study is complete and provides safety data for this treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site
Chitose-shi, Hokkaido, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?
- Could a common diabetes drug weaken your bones?
- Can a spice and a mindset shift ease diabetic nerve pain?
- Ancient wisdom meets modern care: could chinese medicine boost diabetes Self-Management?
- Could a peptide injection help rebuild Insulin-Making cells?
- A pill for diabetes? new oral drug aims to rival injections